Galectin Therapeutics Inc (GALT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $304.57M
Last updated: Nov 17, 2026 at 4:18 PM ET
Galectin Therapeutics Inc (GALT) Statistics
Galectin Therapeutics (GALT) has a market cap of $304.57M and an enterprise value of $326.07M. Its share count is up 39.59% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 7.06% above the market cap, as debt exceeds cash.
| Market Cap | $304.57M |
|---|---|
| Enterprise Value | $326.07M |
| Latest price (Nov 17, 2026) | $2.91 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 47.19% over 52 weeks and trades 18.94% below its 50-day average.
| Beta (1Y) | 1.11 |
|---|---|
| 52-Week Change | -47.19% |
| 1-Month Change | -16.74% |
| 3-Month Change | -20.71% |
| 6-Month Change | +39.90% |
| 5-Year Change | +4.73% |
| 10-Year Change | +361.11% |
| Total Return (1Y) | -47.19% |
| Total Return (3Y CAGR) | +14.08% |
| Total Return (5Y CAGR) | +1.51% |
| Return vs SPY (1Y) | -64.55% |
| Max Drawdown (1Y) | -68.05% |
| Max Drawdown (3Y) | -79.99% |
| Sharpe Ratio (1Y) | -0.83 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $3.59 |
| 200-Day Average | $3.21 |
| 52-Week Range | $2.03 to $7.13 |
| RSI (14 Days) | 36.4 |
| Average Volume (20 Days) | 203.16K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.28x current liabilities.
| Current Ratio | 0.28x |
|---|---|
| Quick Ratio | 0.28x |
| Interest Coverage | -2.47x |
Returns and Efficiency
Return on invested capital is 671.12% over the last 12 months.
| Return on Assets (ROA) | -178.26% |
|---|---|
| Return on Invested Capital (ROIC) | 671.12% |
Scores
GALT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | $12.00K |
| Operating Income | -$14.79M |
| Pretax Income | -$23.19M |
| Net Income | -$23.19M |
| EBIT | -$16.59M |
| Reported EPS (TTM) | -$0.34 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $11.71M |
|---|---|
| Total Debt | $33.21M |
| Net Debt | $21.50M |
| Net Debt Per Share | $0.24 |
| Working Capital | -$33.50M |
| Shareholder Equity | -$35.16M |
| Total Assets | $13.01M |
| Total Liabilities | $46.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$14.61M |
|---|---|
| FCF Per Share | -$0.14 |
| Depreciation and Amortization | $87.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
GALT does not pay a dividend.
| Buyback Yield | -0.68% |
|---|---|
| Shareholder Yield | -0.68% |
Stock Splits
The last split was a 1-for-6 reverse split on Mar 23, 2012.
| Last Split Date | Mar 23, 2012 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 3 similar companies, GALT has the highest ROIC.
ROICPeer median -6.66%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -6.05%
| ROIC | 671.12% vs -6.66% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -6.05% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GALT
What is GALT's market cap?
Galectin Therapeutics has a market cap of $304.57M. Its enterprise value, which adds debt and subtracts cash, is $326.07M.
How many shares of GALT are outstanding?
Galectin Therapeutics has 89.62M shares outstanding. The count is up 39.59% from a year earlier.
Does GALT pay a dividend?
No. Galectin Therapeutics does not pay a dividend.
How much debt does GALT have?
Galectin Therapeutics has $33.21M of total debt and $11.71M of cash and equivalents, a net debt position of $21.50M.
GALT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors